209 results about "Dosing regimen" patented technology

The present disclosure provides methods and dosing regimens for the treatment of depression (e.g., treatment resistant depression) with a mucoadhesive composition comprising N, N-dimethyltryptamine (DMT) or a pharmaceutically acceptable salt thereof.

The invention discloses an anesthesia depth accurate prediction system and method based on time sequence alignment. The method comprises the steps that a cross-modal joint time sequence characteristic data matrix is acquired and generated; outputting a time sequence alignment feature sample; outputting a future advanced prediction label set; obtaining a first-stage anesthesia depth prediction model; in the first anesthesia depth prediction model training stage, a logic auditing link is introduced, and a self-adaptive online updating model is formed; starting an anti-fact dose simulation module, and outputting a candidate anti-fact administration scheme set; and inputting the candidate anti-factual administration scheme set into a dynamic security constraint optimizer, rejecting non-compliant schemes by the dynamic security constraint optimizer according to single maximum dose limitation, single additional dose and administration times in a minimum administration interval, and outputting an optimal administration suggestion. According to the method, combined classification judgment is carried out on the anesthesia state grade and the change trend of each prediction step, and the sensitivity of clinical risk identification and abnormal situation early warning is effectively improved.

The present invention provides dosing regimens of bispecific antibodies that target both CD3 and CD20 when used in the treatment of lymphoma, such as B cell non-Hodgkin lymphoma (B-NHL).

The invention provides an optimal administration method for promoting cervical maturation by misoprostol based on a PopPK model, and belongs to the technical field of drug administration scheme optimization, the method comprises the following steps: constructing the PopPK model for oral administration of misoprostol by a pregnant woman in late pregnancy, the PopPK model is a model structure containing absorption lag time zero-order-first-order absorption parallel, one-atrioventricular distribution and first-order elimination, and the PopPK model is a model structure containing absorption lag time zero-order-first-order absorption parallel, one-atrioventricular distribution and first-order elimination; the PopPK model comprises two absorption chambers and one central chamber; and based on the PopPK model, determining a staged administration scheme through simulation optimization. The limitation of a traditional fixing scheme is effectively overcome, and the safety, effectiveness and clinical practicability of drug administration are considered.

Antibody formulations are described comprising a mixture of an anti-α4β7 antibody, an antioxidant or chelator, and at least one free amino acid. The disclosed formulations may have improved stability, reduced aggregate formation, or both. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-α4β7 antibody in vivo.

Therapeutic use and dosing regimen of anti-ICOS antibodies or antigen-binding fragments thereof for modulating the ratio between regulatory T cells and effector T cells, stimulating the immune system of patients, and / or treating tumours or cancers, as monotherapy or combination therapy, e.g., with anti-PD-L1 antibodies or antigen-binding fragments thereof.

The present invention provides a method for administering psychedelic drugs in a way that avoids or reduces undesirable side effects. [Solution] A method for administering a psychedelic drug to avoid the side effects of hallucinations and perceptual disturbances, comprising: the step of administering the psychedelic drug to an individual in an escalating dosing regimen; and the step of mitigating the side effects of hallucinations and perceptual disturbances.

The invention is a method for treating patients with Parkinson's disease by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose “Off” time, total post dose “On” time and total post dose “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.

The present invention relates to an anti-GDF15 antibody and to a dosage regimen for the treatment of cancer in a human patient using the anti-GDF15 antibody. The present inventors identified a mechanism by which GDF-15 blocks adhesion and transgression of predominantly T-lymphocytes into tissues. Hence, a novel treatment approach has been established by the present invention that facilitates effector T cell entry into tumor tissue upon blockage of GDF-15 using the antibody of the present invention thereby allowing the treatment of cancer in human patients.

The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (GnRH) antagonist without causing a testosterone spike and / or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect.

The present invention provides compositions and methods for treating a hypophosphatemic disorder, such as X-linked hypophosphatemia (XLH). The method entails administering to a subject a pharmaceutical composition containing an anti-FGF23 ligand, wherein the dosing regimen of the pharmaceutical is designed to reach effective and efficient control of FGF23 activity.

The application provides a misoprostol cervical ripening optimization dosing method based on a PopPK model, belongs to the technical field of drug dosing scheme optimization, and comprises the following steps: constructing a PopPK model of oral misoprostol for pregnant women in the third trimester of pregnancy, the PopPK model is a model structure containing zero-order-first-order absorption in parallel, one-compartment distribution and first-order elimination, the PopPK model comprises two absorption compartments and one central compartment; and determining a phased dosing scheme based on the PopPK model through simulation optimization. The method effectively overcomes the limitations of traditional fixed schemes, and takes into account the safety, effectiveness and clinical practicability of dosing.

Provided are pharmaceutical formulations and dosing regimen for antibody-based treatment of amyotrophic lateral sclerosis (ALS).

Methods for treating open-angle glaucoma include transitioning a patient from a twice-per-day or more treatment regimen to a once-per-day treatment regimen. The once-per-day treatment include administering a single dose of a pharmaceutical composition including timolol or a pharmaceutically acceptable salt thereof, brimonidine or a pharmaceutically acceptable salt thereof, dorzolamide or a pharmaceutically acceptable salt thereof, and bimatoprost or a pharmaceutically acceptable salt thereof, once per day.

Liposomal trans-crocetin pharmaceutical compositions, dosing regimens and methods of treating or preventing disorders and conditions associated with, but not limited to, infection, ischemia, hypoxia, ARDS, inflammation, sepsis, shock, stroke, traumatic injury, and proliferative disorders such as cancer are provided. Methods of using the provided trans-crocetin pharmaceutical compositions and dosing regimens to treat cardiovascular, renal, liver, inflammatory, metabolic, pulmonary, neurological, and other disorders and conditions are also provided, as are methods of increasing the delivery of oxygen and increasing the efficacy of a therapeutic agent using the provided compositions and dosing regimens.

To provide dosing regimens of GLP-1 analogs for the treatment of fat, obese, overweight, nonalcoholic fatty liver disease (NAFLD), and / or nonalcoholic steatohepatitis (NASH).SOLUTION: Administering to the subject a first effective amount of one or more first active ingredients selected from the group consisting of GLP-1 and GLP-1 analogs; A dosing regimen is provided, comprising: a first effective amount administered continuously, or intermittently at an interval between two consecutive administrations of six hours or less; and one or more second active ingredients selected from the group consisting of a second effective amount of GLP-I and a GLP-1 analog, administered to said subject once daily, twice daily, three times daily, or four times daily.SELECTED DRAWING: None

The present disclosure provides methods and materials for screening a compound or monitoring a subject's response to a compound or dosing regimen for treating a PGRN-associated disorder. Methods and materials for identifying and treating a subject having a PGRN-associated disorder are also provided.

Antibody formulations are described comprising a mixture of a non-reducing sugar, an anti-α4β7 antibody and at least one amino acid. The disclosed formulations have improved stability, reduced aggregate formation, and may retard degradation of the anti-α4β7 antibody therein or exhibit any combinations thereof. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-α4β7 antibody in vivo.

A method is provided for reducing the treatment burden for patients who have an intraocular neovascular disorder, the method comprising administering a therapeutically effective amount of VEGF antagonist on a dosing schedule that includes treatment intervals of 8 and / or 12 weeks.

A GIT38 human oral dosage regime that provides a (mean AUC(0-24),ss (h*ng / ml)) / (dose (mg)) ratio of less than 5 and / or a (mean AUC(0-24),ss (h*ng / ml)) / (Absolute Neutrophil Count (cells / mm3)) ratio on day 22 of dosing of not greater than 1.25.

A drug administration management method according to one embodiment disclosed herein may comprise the steps of: receiving identification information of a first drug from a pharmacist terminal; transmitting permission information corresponding to the identification information of the first drug to the pharmacist terminal; receiving customized medication guidance, in which the permission information is personalized according to patient profile information of a patient, from the pharmacist terminal, and storing the customized medication guidance in a patient information database; receiving identification information of a drug from a patient terminal and searching for the identification information of the drug in an internal database; and generating a customized administration schedule for the patient according to administration schedule information of the first drug included in the customized medication guidance if the searched identification information of the drug is the identification information of the first drug.

Doses and dosing regimens for incretin analogs are disclosed comprising determining and administering doses of long-acting incretin analogs suitable for once-weekly dosing, such as a glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon (GCG) (GGG) tri-receptor agonist.

Provided are combination dosing regimens comprising administering an antibody-drug conjugate and hyaluronidase. Combinations and compositions containing the antibody-drug conjugate and hyaluronidase are provided. The dosing regimens and combinations are for treating or preventing cancer.

The present invention relates to the dipeptidyl-peptidase I (DPPI or Cathepsin C) inhibitor of formula (I), which is useful in the prevention and / or treatment of bronchiectasis with certain underlying aetiologies, in the prevention and / or treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis or hidradenitis suppurativa using therapeutically efficacious dosages and to polymorphs of Compound (I) as well as to pharmaceutical compositions comprising Compound (I) and its polymorphs.

The present disclosure relates to an oral dosage form, such as a capsule, comprising (a) mirdametinib having a d90 no more than 250 microns, a d50 no more than 50 microns, or both, and (b) one or more pharmaceutically acceptable excipients. These dosage forms are useful in the treatment of tumors and cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), high grade glioma (HGG), low grade ovarian cancer, Langerhans cell histiocytosis (LCH), brain cancer, and a cancer that has metastasized to a patient's brain. The disclosure also related to improved dosage regimens for mirdametinib treatments.

This method involves treating a patient's skin condition or disease by topically applying a pharmaceutical composition containing roflumilast. Treatment methods include once-daily application of the roflumilast composition for a period of time, followed by twice-weekly application of the roflumilast composition as a maintenance dosing regimen.

The invention discloses an application of food-grade sodium carbonate in preparation of a medicine for regulating the acid-base balance of human tissues. The food-grade sodium carbonate conforming to the national food safety standard (GB1886.1) is used as a unique effective component and is dissolved in water to prepare sodium carbonate aqueous solutions with different concentrations, and acid metabolites accumulated in human tissues in local and whole body levels and in human tissues are treated by multiple administration routes such as external use and oral administration. The normal acid-base microenvironment of the tissue is recovered. Wherein the mass concentration of the external preparation is 0.05%-10%, and the mass concentration of the oral preparation is 0.1%-1.5%. The traditional Chinese medicine composition can be used for preventing and / or treating cancers and malignant tumors, stomach diseases related to hyperacidity, femoral head necrosis, muscle strain, frostbite and various diseases taking acid-base imbalance as a common pathological basis. The raw materials are wide in source, low in price and high in safety, the preparation process is simple, the administration scheme is systematic and complete, a single or combined administration route can be flexibly selected according to the specific condition of a patient, and individualized treatment is achieved.